Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy

Documenti analoghi

• Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries
  di: Christian Récher, et al.
  Pubblicazione: (2024)
• Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
  di: Céline Row, et al.
  Pubblicazione: (2024)
• Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor
  di: Gaétan Basile, et al.
  Pubblicazione: (2025)
• Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia—A FILO Study
  di: Corentin Orvain, et al.
  Pubblicazione: (2025)
• Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications
  di: Jean‐Baptiste Rieu, et al.
  Pubblicazione: (2026)